To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin
Condition: Diabetes Mellitus, Type 2 Interventions: Drug: empagliflozin; Drug: Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents Sponsor: Boehringer Ingelheim Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Empagliflozin | Endocrinology | Incretin Therapy | Jardiance | Pancreatitis | Research | SGLT2 Inhibitors | Sodium